Hypermarcas (OTCMKTS:HYPMY) Stock Price Down 4.3% - What's Next?

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares were down 4.3% during mid-day trading on Thursday . The company traded as low as $4.50 and last traded at $4.50. Approximately 3,692 shares were traded during trading, a decline of 79% from the average daily volume of 17,270 shares. The stock had previously closed at $4.70.

Hypermarcas Stock Down 2.1%

The business has a 50 day simple moving average of $4.27 and a 200 day simple moving average of $3.59. The stock has a market cap of $2.91 billion, a PE ratio of 19.17 and a beta of 0.79. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The company reported ($0.04) EPS for the quarter. The business had revenue of $184.34 million for the quarter. Hypermarcas had a return on equity of 6.95% and a net margin of 12.51%.

Hypermarcas Dividend Announcement

The business also recently declared a dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, July 1st will be paid a dividend of $0.0345 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a dividend yield of 2.81%. Hypermarcas's dividend payout ratio (DPR) is presently 45.83%.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.